Multiple myeloma
Conditions
Interventions
treatment group:Carfilzomib-based regimens, including KRd/KPd/DKd/DKRd/DKPd.
Sponsors
Chinese People's Liberation Army Northern Theater Command General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients fully understand this study, voluntarily participate and sign the informed consent form (ICF); 2. Age>=18 years; 3. Newly diagnosed multiple myeloma confirmed by clinical diagnosis; 4. Patients who plan to undergo autologous hematopoietic stem cell transplantation or do not plan to undergo autologous hematopoietic stem cell transplantation; 5. Bortezomib is included in the induction regimen; 6. The efficacy of bortezomib-containing induction therapy for 1 course =CR.
Exclusion criteria
Exclusion criteria: 1. Carfilzomib is not used in induction or consolidation; 2. The efficacy of 1 course of bortezomib-containing induction therapy >=PR; 3. The efficacy of bortezomib-containing induction therapy for 2 courses >=VGPR; 4. MRD detection was not performed at >=CR; 5. Bone marrow dry pumping; 6. Suffering from a serious infection; 7. In the judgment of the investigator, the patient is not suitable to participate in this study; 8. Inability to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRD negative;Overall response rate;Partial response;Very good partial response;Complete response;Strictly complete response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sustained minimal residual disease negative;Progression free survival;Adverse event; | — |
Countries
China
Contacts
Public ContactLiu Jinghua
Chinese People's Liberation Army Northern Theater Command General Hospital
Outcome results
None listed